News

• 14.11.2024
  Bioretec Ltd’s business review January–September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage
• 04.10.2024
  Inside information: Bioretec updates its financial targets
• 04.10.2024
  Inside information: Bioretec updates its product development strategy by accelerating the product development of RemeOs™ Spinal Interbody Cage
• 20.09.2024
  Bioretec’s Shareholders' Nomination Board appointed
• 15.08.2024
  Bioretec Ltd’s half-year report January–June 2024: RemeOs™ trauma screw controlled launch in the U.S. yielded expected positive clinical results
• 27.06.2024
  Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European Marketing Authorization
• 19.06.2024
  Bioretec reports successful clinical outcomes from U.S. controlled launch of RemeOs™ trauma screw: fracture healing confirmed in 100% of surgical procedures
• 18.06.2024
  Bioretec Appoints Frank Sarcone as Vice President of Sales for the US and a member of the Management Team
• 21.05.2024
  Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings - Ilmarinen Mutual Pension Insurance Company